Literature DB >> 2988732

Relation of HTLV-III seropositivity and lymphadenopathy.

E Jeffries, W J Boyko, B Willoughby, P D Constance, B Wiggs, M O'Shaughnessy, F R Sharp.   

Abstract

Testing for antibody to human T-lymphotropic retrovirus (HTLV-III) was carried out in five groups of homosexual men: 250 without lymphadenopathy (control group), 37 with slight or nonpersistent lymph node enlargement (intermediate group), 141 with persistent generalized lymphadenopathy, 32 with persistent generalized lymphadenopathy who underwent biopsy and 11 in whom acquired immune deficiency syndrome (AIDS) was diagnosed. The rates of HTLV-III seropositivity in the five groups were 18%, 32%, 61%, 94% and 91% respectively.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2988732      PMCID: PMC1346021     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  8 in total

1.  HTLV-III antibody frequency and severity of lymphadenopathy.

Authors:  H Bayer; U Bienzle; J Schneider; G Hunsmann
Journal:  Lancet       Date:  1984-12-08       Impact factor: 79.321

2.  Generalized lymphadenopathy in homosexual men.

Authors:  C E Metroka; S Cunningham-Rundles; M S Pollack; J A Sonnabend; J M Davis; B Gordon; R D Fernandez; J Mouradian
Journal:  Ann Intern Med       Date:  1983-11       Impact factor: 25.391

3.  The Vancouver Lymphadenopathy-AIDS Study: 3. Relation of HTLV-III seropositivity, immune status and lymphadenopathy.

Authors:  W J Boyko; M T Schechter; E Jeffries; B Douglas; M Maynard; M O'Shaughnessy
Journal:  Can Med Assoc J       Date:  1985-07-01       Impact factor: 8.262

4.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

5.  The Vancouver Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy.

Authors:  M T Schechter; W J Boyko; E Jeffries; B Willoughby; R Nitz; P Constance
Journal:  Can Med Assoc J       Date:  1985-06-01       Impact factor: 8.262

6.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

7.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

8.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

  8 in total
  1 in total

1.  The Vancouver Lymphadenopathy-AIDS Study: 5. Antecedent behavioural, clinical and laboratory findings in patients with AIDS and HIV-seropositive controls.

Authors:  W J Boyko; M T Schechter; K J Craib; P Constance; R Nitz; S Fay; A McLeod; M O'Shaughnessy
Journal:  CMAJ       Date:  1986-10-15       Impact factor: 8.262

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.